{"doi":"10.3389/fonc.2024.1527331","title":"Exploration of the quantitative-effectiveness association between acupuncture temporal parameters and chemotherapy-induced peripheral neuropathy in cancer patients: a dose-response meta-analysis of randomized controlled trials","abstract":"<jats:sec><jats:title>Background</jats:title><jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is one of the commonly reported symptoms impacting cancer survivors. This study evaluated and compared the effectiveness of acupuncture treatments for CIPN.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We searched six databases from their inception to August 2024 to identify eligible randomized controlled trials (RCTs). Primary outcome were pain scores. Secondary outcomes were quality of life including FACT/GOG-Ntx and EORTC QLQ-C30. The robust error meta-regression (REMR) method was used to evaluate the dose-response relationship across treatment parameters, including number of sessions, frequency, and duration.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In total, 11 RCTs featuring 740 participants were included. The meta-analysis demonstrated that the primary analysis achieved a significant reduction in pain scores, with a standardized mean difference of [SMD= -1.23, 95% CI = (-2.22, -0.24); <jats:italic>P</jats:italic> &amp;lt; 0.01; <jats:italic>I²</jats:italic> = 95%], improvement quality of life including FACT/GOG-Ntx [SMD = 0.95, 95% CI = (0.02, 1.88); <jats:italic>P</jats:italic> &amp;lt; 0.01; <jats:italic>I²</jats:italic> = 93%] and EORTC QLQ-C30 [SMD = 0.36, 95% CI = (0.03, 0.68); <jats:italic>P</jats:italic> = 0.14; <jats:italic>I²</jats:italic> = 46%]. The nonlinear dose-response analysis suggests that pain improvement achieves the MCID at 16 treatment sessions, over 8 weeks, with a frequency of twice per week. Furthermore, analysis of the treatment duration chart shows that acupuncture maintains therapeutic effects during the follow-up period. Sensitivity analysis confirmed the robustness of these findings.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Acupuncture demonstrates significant potential in managing CIPN, particularly through individualized treatment regimens. The identified time-dose-response relationship suggests that tailoring acupuncture frequency and duration can to optimize pain relief in CIPN patients. Future high-quality studies and large-scale multicenter clinical trials are needed to validate these findings.</jats:p></jats:sec>","journal":"Frontiers in Oncology","year":2025,"id":646784,"datarank":0.24141568686511508,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.0,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":416516,"name":"Qin Luo","orcid":"0000-0002-1351-7231","position":1,"is_corresponding":false},{"id":1684815,"name":"Liuyang Huang","orcid":null,"position":2,"is_corresponding":false},{"id":1327582,"name":"Guang Chen","orcid":"0000-0002-7416-592X","position":3,"is_corresponding":false},{"id":1684817,"name":"Mingsheng Sun","orcid":null,"position":4,"is_corresponding":false},{"id":1684818,"name":"Fanrong Liang","orcid":null,"position":5,"is_corresponding":false},{"id":1042566,"name":"Hao Tian","orcid":"0000-0001-5734-913X","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Exploration of the quantitative-effectiveness association between acupuncture temporal parameters and chemotherapy-induced peripheral neuropathy in cancer patients: a dose-response meta-analysis of randomized controlled trials","abstract":"<jats:sec><jats:title>Background</jats:title><jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is one of the commonly reported symptoms impacting cancer survivors. This study evaluated and compared the effectiveness of acupuncture treatments for CIPN.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We searched six databases from their inception to August 2024 to identify eligible randomized controlled trials (RCTs). Primary outcome were pain scores. Secondary outcomes were quality of life including FACT/GOG-Ntx and EORTC QLQ-C30. The robust error meta-regression (REMR) method was used to evaluate the dose-response relationship across treatment parameters, including number of sessions, frequency, and duration.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In total, 11 RCTs featuring 740 participants were included. The meta-analysis demonstrated that the primary analysis achieved a significant reduction in pain scores, with a standardized mean difference of [SMD= -1.23, 95% CI = (-2.22, -0.24); <jats:italic>P</jats:italic> &amp;lt; 0.01; <jats:italic>I²</jats:italic> = 95%], improvement quality of life including FACT/GOG-Ntx [SMD = 0.95, 95% CI = (0.02, 1.88); <jats:italic>P</jats:italic> &amp;lt; 0.01; <jats:italic>I²</jats:italic> = 93%] and EORTC QLQ-C30 [SMD = 0.36, 95% CI = (0.03, 0.68); <jats:italic>P</jats:italic> = 0.14; <jats:italic>I²</jats:italic> = 46%]. The nonlinear dose-response analysis suggests that pain improvement achieves the MCID at 16 treatment sessions, over 8 weeks, with a frequency of twice per week. Furthermore, analysis of the treatment duration chart shows that acupuncture maintains therapeutic effects during the follow-up period. Sensitivity analysis confirmed the robustness of these findings.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Acupuncture demonstrates significant potential in managing CIPN, particularly through individualized treatment regimens. The identified time-dose-response relationship suggests that tailoring acupuncture frequency and duration can to optimize pain relief in CIPN patients. Future high-quality studies and large-scale multicenter clinical trials are needed to validate these findings.</jats:p></jats:sec>","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"40034252","pmcid":"PMC11873836","openalex_id":null,"authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1527331/pdf","host_type":"publisher"},{"url":"https://www.frontiersin.org/articles/10.3389/fonc.2024.1527331/full","host_type":"publisher"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11873836/pdf/fonc-14-1527331.pdf","host_type":"repository"},{"url":"https://doi.org/10.3389/fonc.2024.1527331","host_type":"Unpaywall"},{"url":"https://europepmc.org/articles/PMC11873836","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC11873836?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":[],"mesh_terms":[],"keywords":["Acupuncture","Meta-analysis","Pain Management","Dose-response","Chemotherapy-induced Peripheral Neuropathy"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-09T15:00:17.661787Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}